Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $34. The company’s shares opened today at $33.05.
According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.5% and a 29.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Cardiome Pharma Corp, and Perrigo Company plc.
Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $45, representing a 36.2% upside.
In a report released today, Mizuho Securities also reiterated a Hold rating on the stock with a $31 price target.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $79.08 million and quarterly net profit of $4.6 million. In comparison, last year the company earned revenue of $69.28 million and had a GAAP net loss of $19.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
